Sentrimed is a clinical-stage biopharmaceutical company creating safer, orally dosed oncology therapies that target the cancer biomarker podoplanin (PDPN). PDPN is a transmembrane glycoprotein receptor that enables cancer cells to proliferate and migrate. This prognostic biomarker appears early in cancer transformation, persists through malignant progression, and causes poor clinical outcomes. As a result, targeting PDPN could represent an important advancement in the profiling and treatment of cancer.

The Company’s lead product candidate, MASL® (lenipagrusin alfa),  is an orally administered therapeutic that targets the PDPN receptor. MASL represents a novel approach to addressing common challenges in oncology treatments that contribute to high recurrence rates and poor patient outcomes. Blocking PDPN by MASL inhibits cancer by altering pathways critical to tumor growth, invasion, evasion and resistance. Additionally, MASL triggers necrotic cell death, which causes host anti-tumor immune responses.

MASL has the potential to treat various stages and types of  cancer, many having large populations of patients with elevated PDPN expression. Research to date shows that MASL is well-tolerated and may be suitable for early and advanced stage cancers. An NIH funded human signal trial was recently completed and published supporting the continued development of MASL. Sentrimed is advancing clinical studies to evaluate MASL as a monotherapy and with standard of care treatments. The Company plans to initially study MASL in head and neck cancer, a disease with high rates of recurrence, limited therapeutic options, and a high prevalence of patients with elevated PDPN.

Sentrimed

Org chart

Teams

Offices